Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA

Key Takeaway: Organon Canada and Henlius have launched BILDYOS® and TUZEMTY®, biosimilars to PROLIA and XGEVA, aimed at expanding access to denosumab treatments. This initiative is expected to enhance treatment options for patients requiring denosumab therapy. The launch reflects a strategic move to provide more affordable alternatives in the market.